About Variant Bio
Variant Bio is a company based in Brooklyn (United States) founded in 2018 by Stephane Castel and Kaja Wasik. Variant Bio has raised $127.74 million across 3 funding rounds from investors including Lux Capital. Variant Bio offers products and services including Genomic Discovery Platform, Data Generation Services, and Ethical Research Collaborations. Variant Bio operates in a competitive market with competitors including Viome, Invitae, Color, Everlywell and Newtopia, among others.
- Headquarter Brooklyn, United States
- Founders Stephane Castel, Kaja Wasik
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website variantbio.com
- Social LinkedIn X Instagram
- Total Equity Funding$127.74M (USD)
in 3 rounds
- Latest Funding Round$105M (USD), Series B
Nov 2021
- Investors
Products & Services of Variant Bio
Variant Bio offers a comprehensive portfolio of products and services, including Genomic Discovery Platform, Data Generation Services, and Ethical Research Collaborations.
Platform for analyzing human genes to identify therapy targets.
Services for generating genomic data to support drug development.
Programs for ethical partnerships in genomics and benefit sharing.
Funding Insights of Variant Bio
Variant Bio has successfully raised a total of $127.74M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $105 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $127.74M
- Total Rounds 3
- Last Round Series B — $105M
- First Round $16.64M
(Oct 2019)
- Investors Count 1
All 3 funding rounds of Variant Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $105M | Series B | – | – | – |
| Aug 2020 | $6.1M | Series A | – | – | – |
| Oct 2019 | $16.64M | Series A | – | Lux Capital | – |
1 investors in total: 1 institutional.
Investors in Variant Bio
Variant Bio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Lux Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage technology companies are funded by Lux Capital. | – | luxcapital.com | Menlo Park, United States |
Investor details for Variant Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Variant Bio
49 people are tracked at Variant Bio (13 in leadership, 22 in board & advisors, 14 in team).
| Name | Role | Group |
|---|---|---|
Stephane Castel | Co-Founder | Leadership |
Kaja Wasik | Co-Founder & CSO | Leadership |
Andrew Farnum | CEO | Leadership |
Holly Vance | Chief Operating Officer & Chief Legal Officer | Leadership |
Laura Yerges-Armstrong | VP, Computational Genetics | Leadership |
Mohd Karim | Director, Medical Biology | Leadership |
Kairi Beck | Director Of Finance | Leadership |
S. Todd Meyer | Director, Medicinal Chemistry | Leadership |
Prathap K. | Vp, Partnerships & Business Development | Leadership |
Leslie Hepner | Vice President Operations | Leadership |
Anthony Lee | Associate Director, Software Engineering | Leadership |
Jennifer Brady | Director Of Biology | Leadership |
Steve Bryant | Chief Business Officer | Leadership |
Josh Wolfe | Board Member | Board & advisors |
Bob More | Board Member | Board & advisors |
Stuart Nagae | Board Member | Board & advisors |
Karen Akinsanya | Scientific Advisor | Board & advisors |
Kiran Musunuru | Senior Advisor | Board & advisors |
Keolu Fox | Senior Advisor | Board & advisors |
Julie Sunderland | Board Member | Board & advisors |
29 more people are available in the full profile.
Complete people profiles for Variant Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Variant Bio
3 dated milestones of Variant Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Variant Bio is founded.
- Funding First funding round of $16.6M.
- Funding Latest funding round, Series B, of $105.0M.
Competitors of Variant Bio
Variant Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viome, Invitae, Color, Everlywell and Newtopia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viome.com | 2016 | Los Alamos, United States | $301.57M | 136 | Machine learning-based bioinformatics solutions for health insights are provided. | |
| invitae.com | 2010 | San Francisco, United States | $189.56M | 1,700 | Home-based genetic tests for detecting diseases are provided to individuals. | |
| color.com | 2013 | Burlingame, United States | $506.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| everlywell.com | 2014 | Austin, United States | $330M | 614 | At-home health tests for biomarkers, nutrition, and hormone analysis. | |
| newtopia.com | 2008 | New York, United States | $13.1M | – | Health management platform is provided for employers and insurers. | |
| geneplanet.com | 2008 | Ljubljana, Slovenia | $34.02M | – | DNA-based personalized health and fitness recommendations are offered. | |
| counsyl.com | 2007 | San Francisco, United States | $112.89M | 503 | DNA mapping for pre-pregnancy genetic testing, DNA and cancer screening | |
| digbihealth.com | 2018 | Mountain View, United States | $5.4M | – | Personalized healthcare is delivered through DNA and gut biome testing. | |
| goodstartgenetics.com | 2008 | Boston, United States | $32.16M | – | Molecular diagnostics for inherited genetic disease screening are provided. |
Detailed competitors of Variant Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Variant Bio
The website of Variant Bio (variantbio.com) receives about 3.9K visits a month and ranks #10,895,156 among all websites worldwide, #8,008 in Biotechnology and Pharmaceuticals.
- Monthly visits3.9K
▲ 189.1% vs previous month
- Global rank#10,895,156
among all websites
- Category rank#8,008
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit1.9
- Average visit47 sec
- DevicesDesktop 40% · Mobile 60%
Latest news on Variant Bio
Complete news archive for Variant Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Variant Bio
10 companies that operate in the same segment as Variant Bio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Variant Bio
Variant Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Variant Bio is headquartered in Brooklyn, United States. It is registered at Brooklyn, New York, United States.
Andrew Farnum is the current CEO of Variant Bio.
Variant Bio is a funded company, having raised a total of $127.74M across 3 funding rounds to date. The company's 1st funding round was a Series A of $16.64M, raised on Oct 2019.
Variant Bio was founded in 2018 and is headquartered in Brooklyn, United States. The company operates in the biotechnology sector, focusing on genomics to address rare diseases. A platform is provided for detecting human genetic diversity, enabling the development of targeted treatment solutions. Services emphasize personalized therapeutics derived from genetic analysis to support therapeutic advancements in underserved medical areas.
Variant Bio offers Genomic Discovery Platform, Data Generation Services, and Ethical Research Collaborations.
Variant Bio has 1 investor. Key investors include Lux Capital.